Patents Assigned to UCP GEN-Pharma AG
-
Publication number: 20020142414Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.Type: ApplicationFiled: January 22, 2001Publication date: October 3, 2002Applicant: UCP Gen-Pharma AGInventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemuller, Hans Fritz, Walter Marki, Sefik Alkan
-
Patent number: 6436901Abstract: The present invention provides a freeze dried pharmaceutical composition comprising hirudin, potassium phosphate and a sugar.Type: GrantFiled: May 3, 1999Date of Patent: August 20, 2002Assignees: UCP Gen-Pharma AG, Novartis CorporationInventor: Tudor Arvinte
-
Patent number: 6342373Abstract: The invention relates to DNA sequences which code an eglin, expression plasmids containing such DNA sequences, hosts transformed with such expression plasmids, novel eglin compounds produced from such transformed hosts, monoclonal antibodies against eglins, hybridoma cells which produce such antibodies, and test kits for immunoassays containing such antibodies, and furthermore the processes for their preparation and a process for the preparation of eglins with the aid of the transformed hosts. The eglins which can be prepared according to the invention have useful pharmacological properties.Type: GrantFiled: May 24, 1991Date of Patent: January 29, 2002Assignee: UCP GEN-Pharma AGInventors: Hans Rink, Manfred Liersch, Peter Sieber, Werner Rittel, Francois Meyer, Ursula Seemüller, Hans Fritz, Walter Märki, Sefik Alkan
-
Patent number: 6103515Abstract: A novel process for the production of heterologous proteins including the use of certain transformed protease deficient yeast strains is provided. The invention concerns also said transformed yeast strains and methods for the production thereof.Type: GrantFiled: June 8, 1992Date of Patent: August 15, 2000Assignees: Novartis Corporation, UCP Gen-Pharma AGInventors: Hansjorg Treichler, Kenji Takabayashi, Dieter Heinrich Wolf, Jutta Heim
-
Patent number: 5972698Abstract: The present invention relates to novel inhibitors of human tryptase, to their isolation from leeches, to nucleotide sequences encoding the novel inhibtor molecules or fragments thereof, to vectors containing the coding sequence thereof, to host cells transformed with such vectors, to the recombinant production of the inibitors, to pharmaceutical compositions containing the novel inhibitor molecules, and to their use in diagnosis and therapy.Type: GrantFiled: January 25, 1996Date of Patent: October 26, 1999Assignees: Novartis Corporation, UCP Gen-Pharma AGInventors: Hans Fritz, Christian Sommerhoff
-
Patent number: 5422249Abstract: The invention relates to DNA sequences that code for the amino acid sequence of the thrombin inhibitor hirudin, hybrid vectors containing such DNA sequences, host cells transformed with such hybrid vectors, novel polypeptides with thrombin-inhibiting activity produced from such transformed host cells, processes for the manufacture of these DNA sequences, hybrid vectors and transformed host cells, and processes for the manufacture of these thrombin-inhibitors using the transformed host cells. The hirudin compounds that can be produced according to the invention have valuable pharmacological properties.Type: GrantFiled: September 15, 1993Date of Patent: June 6, 1995Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AGInventors: Manfred Liersch, Hans Rink, Walter Marki, Markus G. Grutter, Bernd Meyhack
-
Patent number: 5268296Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques. DNA sequences encoding hirullins P6 and P18 are supplied, hybrid vectors and transformed microorganisms for recombinant hirullin production are supplied.Type: GrantFiled: February 21, 1992Date of Patent: December 7, 1993Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AGInventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter
-
Patent number: 5180667Abstract: DNA encoding novel eglin mutants that differ from the natural eglins B and C by the replacement of amino acids in the region of the active center (amino acid 45) by other amino acids are provided. The mutants, which are produced by recombinant genetic engineering, have valuable pharmacological properties.Type: GrantFiled: October 11, 1991Date of Patent: January 19, 1993Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma, AGInventors: Markus G. Grutter, Dirk Heinz, Manfred Liersch
-
Patent number: 5126134Abstract: There is provided a pharmaceutical composition comprising as component A a plasminogen activator and as component B hirudin together with a pharmaceutically acceptable carrier. The pharmaceutical composition can be used for the prophylaxis and therapy of thrombosis or diseases caused by thrombosis.Type: GrantFiled: September 18, 1989Date of Patent: June 30, 1992Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AGInventors: Jutta Heim, Giancarlo Agnelli, Czeslaw Czendlik
-
Patent number: 5114922Abstract: Novel polypeptides, designated hirullins, have a strong antithrombic activity and can therefore be used for the therapy and prophylaxis of thromboses. Said compounds are isolated from the leech Hirudinaria manillensis or are produced by conventional peptide synthesis or by recombinant DNA techniques.Type: GrantFiled: June 8, 1989Date of Patent: May 19, 1992Assignees: Ciba-Geigy Corporation, UCP Gen-Pharma AGInventors: Reinhard Maschler, Verena Steiner, Markus G. Grutter, Fritz Raschdorf